Gilead Sciences (GILD) Raw Materials (2009 - 2015)
Gilead Sciences' (GILD) quarterly Raw Materials came in at $1.3 billion in Q4 2015, up 46.53% YoY from $909.0 million in Q4 2014, and up 46.53% on a QoQ basis from $909.0 million in Q4 2014.
Gilead Sciences (GILD) Raw Materials (2009 - 2015) Analysis & Trends
Gilead Sciences (GILD) has 7 years of Raw Materials data on file, last reported at $1.3 billion in Q4 2015.
- Quarterly Raw Materials rose 46.53% year-over-year to $1.3 billion in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $1.3 billion (up 46.53% YoY) and the FY2015 annual result came in at $1.3 billion, up 46.53% from the prior year.
- Raw Materials advanced to $1.3 billion in Q4 2015, from $909.0 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $1.3 billion in Q4 2015 to a low of $559.2 million in Q1 2011.
- A 5-year average of $872.3 million and a median of $866.4 million in 2011 frame the typical range for Raw Materials.
- Annual changes were most pronounced in 2011 — Raw Materials surged 96.23% — and 2014, when it slipped 13.38%.
- Tracing GILD's Raw Materials over 5 years: stood at $697.6 million in 2011, then climbed by 18.48% to $826.5 million in 2012, then increased by 26.96% to $1.0 billion in 2013, then fell by 13.38% to $909.0 million in 2014, then soared by 46.53% to $1.3 billion in 2015.
- The last three Raw Materials figures came in at $1.3 billion (Q4 2015), $909.0 million (Q4 2014), and $944.9 million (Q2 2014), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 1.33 Bn |
| Dec 31, 2014 | 909.00 Mn |
| Jun 30, 2014 | 944.89 Mn |
| Dec 31, 2013 | 1.05 Bn |
| Dec 31, 2012 | 826.55 Mn |
| Dec 31, 2011 | 697.62 Mn |
| Sep 30, 2011 | 866.41 Mn |
| Jun 30, 2011 | 665.25 Mn |
| Mar 31, 2011 | 559.16 Mn |
| Dec 31, 2010 | 408.02 Mn |
| Sep 30, 2010 | 441.53 Mn |
| Dec 31, 2009 | 333.58 Mn |